The current medical literature contains many reports of studies with oral hypoglycemic agents.1-3 These substances thus far have been sulfonylurea derivatives with blood-sugar-lowering ability in certain types of diabetes. Within the last year studies were started with a new group of compounds classified as formamidinyliminoureas. These drugs are biguanides, not to be confused with the diguanidines, which include Synthalin (guanidine-deca-methylene-guanidine) (Fig. 1). They also have no structural relationship to either carbutamide or tolbutamide and have no sulfonyl radical in their formulae. Ungar et al.4 recently reported that one of these agents, phenethylformamidinyliminourea hydrochloride, was effective orally in both normal and alloxandiabetic animals. He also reported5 the uptake of glucose by a rat diaphragm preparation. Williams6 reported a hypoglycemic effect in animals, and Nielsen et al.7 stated that this hypoglycemic effect was observed in depancreatized animals. Pomeranze8 first demonstrated successful hypoglycemic effects in clinical trials with patients.
This present report is
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 28
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.